Pharma News

Ipsen (OTC: IPSEY) has agreed to acquire Albireo Pharma Inc (NASDAQ: ALBO) at $42.00 per share in cash for an initial estimated aggregate consideration of $952 million plus one contingent value right ...

AstraZeneca has inked a definitive agreement to acquire cardiorenal disease player CinCor Pharma in a deal that could potentially reach $1.8 billion in total value, the companies announced Monday....

Chiesi Farmaceutici expects that the deal will expand its rare disease medicine portfolio.

Ublituximab-xiiy from TG Therapeutics Inc is the first anti-CD20 monoclonal antibody approved for individuals with RMS that is administered as a 1-hour infusion after the starting dose. ...

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

The FDA has granted Breakthrough Therapy designation to Vaxcyte for its VAX-24, an investigational 24-valent pneumococcal conjugate vaccine to prevent invasive pneumococcal disease, a group of bact...

Biogen’s efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China’s InnoCare last year for $...

The FDA has approved Roche’s Actemra (tocilizumab) for intravenous treatment of hospitalized adults who have COVID-19 and are receiving systemic corticosteroids and require supplemental oxygen, ...

The FDA has granted accelerated approval to Roche’s Lunsumio (mosunetuzumab-axgb) for the treatment of adult patients with relapsed or resistant follicular lymphoma (a common type of non-Hodgkin ...

First direct evidence of diminished 5-HT release proves hypothesis, according to a new analysis published in Biological Psychiatry.

Researchers at Karolinska Institutet have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not.  ...

The FDA has granted approval to Gilead Sciences’ Sunlenca (lenacapavir) for treatment of adults with human immunodeficiency virus (HIV) type 1 whose HIV infections can’t be treated with other ...